You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
EXAS April options mis-priced
- Thread starter vanv0029
- Start date
Quote from atticus:
The off-label (for lack of a better term) use in Crohn's and IBS would be a huge potential market. I >doubled my action this morning on the dip. Avg on the long is now 10.60.
Yup.
That right there is 1.4 million potential annual tests.
http://www.ncbi.nlm.nih.gov/pubmed?cmd=PureSearch&term=(ahlquist da[Author] AND mayo[All Fields])
Quote from Landis82:
The market-cap is only $670 million.
There are 5.8 million shorts out there that have been betting on management not being able to execute. Thus far, they have met their guidance every step of the way.... and have only been one month behind their "time-line" that was offered over 2 years ago.
In the past, if you have bet against CEO Kevin Conroy you have lost.
I'm long the may buy rite.
I don't think 8percent short interest is meaningful.
Quote from Landis82:
So why do you feel the need to "comment" on a Company and technology that you know nothing about?
i was NOT commenting on a company or technology.
i agree i don't know anything about the company or the technology.
i was just trying to help others traders realize that not everything drug will approval at each step and that they should hedge/position size accordingly.
so unless you went to harvard medical school you can't comment on a trade? this is elite trader not elite doctor.
i'm done positioning my trade:
33% long may 12 buywrite (cost basis 9.5)
66% long common with may 9 - 12 collar (cost basis 11)
33% long may 12 buywrite (cost basis 9.5)
66% long common with may 9 - 12 collar (cost basis 11)